Free Trial

Delma Caiati Analyst Performance

Analyst at Guggenheim

Delma Caiati is a stock analyst at Guggenheim in the healthcare sector, covering 6 publicly traded companies. Over the past year, Delma Caiati has issued 6 stock ratings, including buy and hold recommendations. While full access to Delma Caiati's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Delma Caiati's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
6 Last 0 Years
Buy Recommendations
83.33% 5 Buy Ratings
Companies Covered
6 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy83.3%5 ratings
Hold16.7%1 ratings
Sell0.0%0 ratings

Out of 6 total stock ratings issued by Delma Caiati at Guggenheim, the majority (83.3%) have been Buy recommendations, followed by 16.7% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
6 companies

Delma Caiati, an analyst at Guggenheim, currently covers 6 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
6 companies
100.0%

Delma Caiati of Guggenheim specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
4 companies
66.7%
BIOTECHNOLOGY
2 companies
33.3%

Delma Caiati's Ratings History at Guggenheim

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
10/6/2026Initiated Coverage$144.21$207.00Buy
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
10/6/2026Initiated Coverage$37.57$73.00Buy
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
10/5/2026Initiated Coverage$32.19$65.00Buy
Maplight Therapeutics, Inc. stock logo
MPLT
Maplight Therapeutics
10/5/2026Initiated Coverage$9.27Neutral
LB Pharmaceuticals Inc stock logo
LBRX
LB Pharmaceuticals
10/5/2026Initiated Coverage$34.62$80.00Buy
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
10/5/2026Initiated Coverage$2.35$7.00Buy